Drugs / PD-L1 t-haNK cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06161545 | Sep 2025 → Dec 2026 expected | head and neck squamous cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-L1 t-haNK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06161545 ↗ |
| Action | Deplete | “PD-L1 t-haNK can lyse such T-cell-resistant tumor cells.” NCT06161545 ↗ |
| Modality | Cell therapy | “PD-L1 t-haNK cells is an allogenic, irradiated (no engraftment), off-the-shelf cell line currently being studied” NCT06161545 ↗ |
| Route | Intravenous | “administered via IV infusion” NCT06161545 ↗ |